Revelation Biosciences, Inc. (REVBW) Stock Ticker

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering immunology-based therapies and diagnostic tools aimed at preventing and treating a range of illnesses. Their flagship therapeutic, REVTx-99, is an intranasal immunomodulator designed to both prevent and treat a broad spectrum of respiratory viral infections, including SARS-CoV-2 (and its variants), influenza A and B, parainfluenza, rhinovirus, and RSV. Furthermore, its potential extends to addressing allergic rhinitis and chronic nasal congestion. The company's pipeline also includes REVTx-200, an intranasal immunomodulator intended as an adjunct to enhance the efficacy of intramuscular vaccinations, thereby boosting immunity. Additionally, they are developing REVDx-501, a rapid diagnostic test designed for convenient home use to detect respiratory viral infections. Established in 2019, the company is headquartered in New York, New York.

REVBW stock facts

What you can see for REVBW on Tickr

Live REVBW price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the REVBW report.

Rankings